OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology Research is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach	102
Liver injury is associated with severe coronavirus disease 2019 (COVID‐19) infection: A systematic review and meta‐analysis of retrospective studies	96
Evidence‐based clinical practice guidelines for liver cirrhosis 2020	87
Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update	62
Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update	60
Longitudinal changes of liver function and hepatitis B reactivation in COVID‐19 patients with pre‐existing chronic hepatitis B virus infection	59
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020	58
MAFLD: Renovation of clinical practice and disease awareness of fatty liver	53
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis	47
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)	42
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)	41
Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan	38
Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: Data from Hong Kong	37
Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study	36
Report of the 21st Nationwide Follow‐up Survey of Primary Liver Cancer in Japan (2010–2011)	35
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study	32
Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma	32
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice	32
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy	30
Diagnostic accuracy of FibroScan‐AST score to identify non‐alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non‐alcoholic fatty liver disease: Comparison betw	30
Hepatocellular carcinoma after Fontan surgery: A systematic review	29
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria	29
Clinical and anthropometric characteristics of non‐obese non‐alcoholic fatty liver disease subjects in Japan	28
Clinicopathological characteristics of combined hepatocellular cholangiocarcinoma from the viewpoint of patient prognosis after hepatic resection: High rate of early recurrence and its predictors	28
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease	27

Analysis of the optimal psoas muscle mass index cut‐off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people	27
Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis	27
Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imaging‐determined proton density fat fraction	27